Tryp Inc

Neurogan is a trusted source for premium CBD products in San Diego, CA. With a focus on natural wellness, they have been providing high-quality cannabinoid supplements since 2016. Their outdoor-grown, high-potency CBD products are crafted with care to enhance overall well-being, offering a diverse range of solutions for sleep, stress, aches, recovery, mood, and skincare. Neurogan is committed to consistency and safety, ensuring their formulas are always in stock and undergo rigorous testing for purity and potency. With a 100% satisfaction guarantee and a price match policy, Neurogan is dedicated to providing customers with the best quality CBD oil for a peaceful mind and a restful body.Generated from the website

Sigyn Therapeutics, Inc. is a San Diego-based company focused on developing innovative blood purification solutions aimed at enhancing the efficacy of drug therapies for cancer and infectious diseases. Their flagship products, ImmunePrep and ChemoPrep, are designed to optimize the delivery of therapeutic antibodies and chemotherapies, while ChemoPure aims to reduce the toxicity of chemotherapy treatments. With a keen emphasis on addressing unmet health needs, Sigyn Therapy targets untreatable viral pathogens, antibiotic-resistant bacterial infections, endotoxemia, and sepsis. The company is committed to creating medical technologies that offer strategic advantages in the healthcare industry by overcoming clearly defined therapeutic limitations. Generated from the website

Amarillo Biosciences is a biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 20.6 percent of Amarillo Biosciences shares and has provided more than $16.5 million in loans, grants and equity investments. The company's primary focus is extensive and ongoing research and development into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Beh et s disease, and opportunistic infections in patients who are HIV positive. In its 20-year history, the company has invested almost $37 million to establish oral interferon as a therapeutic agent. The overwhelming majority of those funds were invested in clinical trials in an effort to achieve Federal Drug Administration approval for interferon.